Physician profile
Mir Subla
NPI 1871577379
$4,714.05
in general payments reported to CMS, 2019-2025
16 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,321 · 2021: $175 · 2022: $471 · 2023: $121 · 2024: $1,514 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $887 · Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $887.20 |
| Food and Beverage | $859.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,249.10 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $1,489.52 | 2022-2025 | Micra, Onyx Frontier, Complete Se Vascular |
| Abbott Laboratories | $250.75 | 2019-2024 | Xience Skypoint, Dragonfly Opstar |
| Abiomed | $234.97 | 2022-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.39 | 2021-2025 | Lifevest |
| Shockwave Medical, INC | $73.16 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals Lp | $44.38 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.85 | 2021 | |
| Boston Scientific Corporation | $31.32 | 2022 | |
| Merck Sharp & Dohme LLC | $26.97 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.80 | 2022 | |
| Teleflex LLC | $25.01 | 2023 | Manta |
| Livanova USA, INC. | $18.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.19 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Subla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.